Cargando…

Severe CMV Infection after Chemo-Immunotherapy with Dose-Reduced Bendamustine and Rituximab in a Mantle Cell Lymphoma Old Patient

Detalles Bibliográficos
Autores principales:	Magliano, Gabriele, Cuccaro, Annarosa, d’Alo’, Francesco, Maiolo, Elena, Bellesi, Silvia, Hohaus, Stefan, Bacigalupo, Andrea, Pagano, Livio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425343/ https://www.ncbi.nlm.nih.gov/pubmed/34527206 http://dx.doi.org/10.4084/MJHID.2021.054

Ejemplares similares

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis
por: Hohaus, Stefan, et al.
Publicado: (2020)

Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization
por: Hohaus, Stefan, et al.
Publicado: (2018)

Vitamin D deficiency and supplementation in patients with aggressive B‐cell lymphomas treated with immunochemotherapy
por: Hohaus, Stefan, et al.
Publicado: (2017)

P1091: CLINICAL IMPLICATIONS OF T CELL SUBSET COMPOSITION DURING MAINTENANCE THERAPY AFTER FIRST-LINE IMMUNOCHEMOTHERAPY CONTAINING BENDAMUSTINE IN PATIENTS WITH FOLLICULAR LYMPHOMA
por: Malafronte, Rosalia, et al.
Publicado: (2023)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Mantle Cell Lymphoma Relapsing at the Lymphedematous Arm
por: Massini, Giuseppina, et al.
Publicado: (2013)

PD‐L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma
por: Cuccaro, Annarosa, et al.
Publicado: (2022)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2022)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

Healthy Organs Uptake on Baseline (18)F-FDG PET/CT as an Alternative to Total Metabolic Tumor Volume to Predict Event-Free Survival in Classical Hodgkin's Lymphoma
por: Morland, David, et al.
Publicado: (2022)

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
por: Gressin, Rémy, et al.
Publicado: (2019)

Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden
por: Leccisotti, Lucia, et al.
Publicado: (2022)

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
por: Nakamura, Nobuhiko, et al.
Publicado: (2022)

Multicolor flow cytometry on pericardial effusion for a prompt diagnosis and treatment of hematological malignancies with heart involvement
por: Cappannoli, Luigi, et al.
Publicado: (2022)

Endoscopic Ultrasound-Guided Fine Needle Biopsy in the Diagnostic Work-Up of Deep-Seated Lymphadenopathies and Spleen Lesions: A Monocentric Experience
por: Bellisario, Flaminia, et al.
Publicado: (2023)

P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL
por: Phillips, Tycel, et al.
Publicado: (2023)

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
por: Hess, Georg, et al.
Publicado: (2020)

Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin
por: Wollina, Uwe, et al.
Publicado: (2019)

Bendamustine/dexamethasone/rituximab: Cytomegalovirus reactivation : case report
Publicado: (2021)

Bendamustine/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Bendamustine/rituximab: Neutropenia, fever and inflammation: case report
Publicado: (2022)

CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma
por: Cuccaro, Annarosa, et al.
Publicado: (2016)

Prognostic Factors in Hodgkin Lymphoma
por: Cuccaro, Annarosa, et al.
Publicado: (2014)

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022)

Burkitt Lymphoma as Fourth Neoplasia in a Patient Affected by Cowden Syndrome with a Novel PTEN Germline Pathogenic Variant
por: Galli, Eugenio, et al.
Publicado: (2020)

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study
por: Yamasaki, Satoshi, et al.
Publicado: (2021)

Epstein-Barr Virus (EBV)-Associated Haemophagocytic Syndrome
por: Torti, Lorenza, et al.
Publicado: (2012)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab
por: Crowhurst, Thomas, et al.
Publicado: (2020)

Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma
por: Schalk, Enrico, et al.
Publicado: (2023)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
por: Qu, Chang-Ju, et al.
Publicado: (2023)

Perforating Folliculitis Secondary to Bendamustine-Rituximab Chemotherapy: A Case Report
por: Monteiro, Rowan, et al.
Publicado: (2017)

Painful, plantar nodules in cutaneous macroglobulinosis: Successful treatment with rituximab and bendamustine
por: D'Acunto, Carmine, et al.
Publicado: (2020)

Two rare cases of bronchus‐associated lymphoid tissue lymphoma successfully treated with rituximab‐bendamustine
por: Panitz, Nydia, et al.
Publicado: (2021)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bqk5s41hdmt0nt5i1isnjpsmt5